Laurus Labs Ltd. reported strong financial performance for the quarter ended March 31, 2025 (Q4FY25), with a remarkable 211% year-on-year (YoY) increase in net profit, driven by higher revenues and a favorable base effect.
Q4FY25 (YoY) Key Financial Highlights:
-
Revenue from operations stood at ₹1,720.30 crore, rising 19.5% from ₹1,439.67 crore in Q4FY24.
-
Total income came in at ₹1,778.87 crore compared to ₹1,458.20 crore a year ago.
-
Profit before tax rose sharply to ₹312.34 crore, up from ₹107.27 crore.
-
Net profit after tax jumped to ₹233.87 crore, compared to ₹75.32 crore in Q4FY24, marking a 211% YoY increase.
-
Total expenses rose moderately to ₹1,466.53 crore from ₹1,350.93 crore last year, largely due to higher employee costs and operating expenses.
Full-Year FY25 Performance:
-
Revenue from operations for FY25 stood at ₹5,553.96 crore, up from ₹5,040.83 crore in FY24.
-
Net profit for the full year was ₹354.41 crore, more than double the previous year’s ₹168.21 crore.
Segment Insights:
The growth was broad-based, with strong contributions from its Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organisation (CDMO), and generics businesses. Employee benefit expenses and depreciation increased slightly due to expansions.
Profit Attribution:
-
Profit attributable to equity holders: ₹233.67 crore
-
Profit attributable to non-controlling interests: ₹(0.90) crore
Laurus Labs continues to strengthen its position in the global pharma supply chain and remains optimistic about growth momentum in FY26.
Disclaimer: The information provided here is for informational purposes only. Please consult your financial advisor before making any investment decisions.
